M42, an Abu Dhabi-based health technology company, has introduced an artificial intelligence-powered tool for prostate cancer ...

Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

What we choose to call cancer may shape patients’ behavior in ways that influence their health outcomes. Relabeling low-grade ...

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today ...

Prostate cancer is the most common cancer in men and is second most common cause of cancer deaths. Importantly, the annual rates of prostate cancer incidence continue to rise. This session will delve ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

ABU DHABI, 8th June, 2026 (WAM) -- M42’s National Reference Laboratory (NRL) has collaborated with digital pathology innovator Qritive to introduce advanced AI-powered prostate cancer diagnostics in ...

Here is how robotic surgeries are paving way for new gen cancer treatment in the country - Read on to know all about it.